DIVIS LABORATORIES
Quarterly Results Analysis [Sep2024]
DIVIS LABORATORIES Quarterly Results
Consolidated | Sep2024 UnAudited |
Jun2024 Audited |
Mar2024 UnAudited |
Dec2023 UnAudited |
Sep2023 UnAudited |
Jun2023 UnAudited |
Mar2023 Audited |
Dec2022 UnAudited |
---|---|---|---|---|---|---|---|---|
Revenues | ₹2,338 Cr | ₹2,118 Cr | ₹2,303 Cr | ₹1,855 Cr | ₹1,909 Cr | ₹1,778 Cr | ₹1,951 Cr | ₹1,708 Cr |
Expenses | ₹1,622 Cr | ₹1,496 Cr | ₹1,572 Cr | ₹1,366 Cr | ₹1,430 Cr | ₹1,274 Cr | ₹1,464 Cr | ₹1,299 Cr |
Operating Income | ₹716 Cr | ₹622 Cr | ₹731 Cr | ₹489 Cr | ₹479 Cr | ₹504 Cr | ₹487 Cr | ₹409 Cr |
Other Income | ₹106 Cr | ₹79 Cr | ₹79 Cr | ₹95 Cr | ₹86 Cr | ₹81 Cr | ₹66 Cr | ₹113 Cr |
Interest | ₹1 Cr | ₹0 Cr | ₹2 Cr | ₹0 Cr | ₹1 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr |
Depreciation | ₹99 Cr | ₹97 Cr | ₹95 Cr | ₹95 Cr | ₹95 Cr | ₹93 Cr | ₹87 Cr | ₹87 Cr |
Profit Before Tax | ₹722 Cr | ₹604 Cr | ₹713 Cr | ₹489 Cr | ₹469 Cr | ₹492 Cr | ₹466 Cr | ₹435 Cr |
Profit After Tax | ₹510 Cr | ₹430 Cr | ₹538 Cr | ₹358 Cr | ₹348 Cr | ₹356 Cr | ₹321 Cr | ₹306 Cr |
EPS | ₹19.25 | ₹16.23 | ₹20.30 | ₹13.51 | ₹13.13 | ₹13.43 | ₹12.11 | ₹11.55 |
Industry Peers & Returns | 1W | 1M | 1Y |
DIVIS LABORATORIES | -1.2% | 3.4% | 65% |
SUN PHARMACEUTICAL INDUSTRIES | 1.6% | 0.1% | 46.2% |
CIPLA | -2.3% | -5.4% | 24.4% |
DR REDDYS LABORATORIES | 3.2% | -2.2% | 5.8% |
ZYDUS LIFESCIENCES | 1.3% | -2.6% | 51.8% |
MANKIND PHARMA | 2.2% | -4.2% | 35.5% |
TORRENT PHARMACEUTICALS | 1.1% | 5.1% | 55.7% |
LUPIN | 3.7% | -2.9% | 62.1% |
AUROBINDO PHARMA | -1.5% | -11.6% | 21.7% |
DIVIS LABORATORIES Quarterly Revenues
Revenues | |
---|---|
Q-o-Q | 10.39 % |
Y-o-Y | 22.47 % |
Quarters | Revenues | % Change | |
---|---|---|---|
Sep2024 | ₹2,338 Cr | 10.39 | |
Jun2024 | ₹2,118 Cr | -8.03 | |
Mar2024 | ₹2,303 Cr | 24.15 | |
Dec2023 | ₹1,855 Cr | -2.83 | |
Sep2023 | ₹1,909 Cr | 7.37 | |
Jun2023 | ₹1,778 Cr | -8.87 | |
Mar2023 | ₹1,951 Cr | 14.23 | |
Dec2022 | ₹1,708 Cr | - |
DIVIS LABORATORIES Quarterly Operating Profit
Operating Profit | |
---|---|
Q-o-Q | 15.11 % |
Y-o-Y | 49.48 % |
Quarters | Operating Profit | % Change | |
---|---|---|---|
Sep2024 | ₹716 Cr | 15.11 | |
Jun2024 | ₹622 Cr | -14.91 | |
Mar2024 | ₹731 Cr | 49.49 | |
Dec2023 | ₹489 Cr | 2.09 | |
Sep2023 | ₹479 Cr | -4.96 | |
Jun2023 | ₹504 Cr | 3.49 | |
Mar2023 | ₹487 Cr | 19.07 | |
Dec2022 | ₹409 Cr | - |
Operating Margins | |
---|---|
Q-o-Q | 4.26 % |
Y-o-Y | 22.04 % |
Quarters | Operating Margin% | % Change | |
---|---|---|---|
Sep2024 | 30.62% | 4.26 | |
Jun2024 | 29.37% | -7.47 | |
Mar2024 | 31.74% | 20.41 | |
Dec2023 | 26.36% | 5.06 | |
Sep2023 | 25.09% | -11.50 | |
Jun2023 | 28.35% | 13.58 | |
Mar2023 | 24.96% | 4.22 | |
Dec2022 | 23.95% | - |
DIVIS LABORATORIES Quarterly Profit After Tax
Profit After Tax(PAT) | |
---|---|
Q-o-Q | 18.60 % |
Y-o-Y | 46.55 % |
Quarters | Profit After Tax | % Change | |
---|---|---|---|
Sep2024 | ₹510 Cr | 18.60 | |
Jun2024 | ₹430 Cr | -20.07 | |
Mar2024 | ₹538 Cr | 50.28 | |
Dec2023 | ₹358 Cr | 2.87 | |
Sep2023 | ₹348 Cr | -2.25 | |
Jun2023 | ₹356 Cr | 10.90 | |
Mar2023 | ₹321 Cr | 4.90 | |
Dec2022 | ₹306 Cr | - |
PAT Margins | |
---|---|
Q-o-Q | 7.44 % |
Y-o-Y | 19.64 % |
Quarters | PAT Margin(%) | % Change | |
---|---|---|---|
Sep2024 | 21.81 % | 7.44 | |
Jun2024 | 20.3 % | -13.10 | |
Mar2024 | 23.36 % | 21.04 | |
Dec2023 | 19.3 % | 5.87 | |
Sep2023 | 18.23 % | -8.94 | |
Jun2023 | 20.02 % | 21.70 | |
Mar2023 | 16.45 % | -8.20 | |
Dec2022 | 17.92 % | - |
DIVIS LABORATORIES Quarterly Earnings Per Share (EPS)
EPS | |
---|---|
Q-o-Q | 18.61 % |
Y-o-Y | 46.61 % |
Quarters | EPS | % Change | |
---|---|---|---|
Sep2024 | ₹19.25 | 18.61 | |
Jun2024 | ₹16.23 | -20.05 | |
Mar2024 | ₹20.3 | 50.26 | |
Dec2023 | ₹13.51 | 2.89 | |
Sep2023 | ₹13.13 | -2.23 | |
Jun2023 | ₹13.43 | 10.90 | |
Mar2023 | ₹12.11 | 4.85 | |
Dec2022 | ₹11.55 | - |
You may also like the below Video Courses
SUN PHARMACEUTICAL INDUSTRIES LTD vs CIPLA LTD vs DR REDDYS LABORATORIES LTD
ZYDUS LIFESCIENCES LTD vs DIVIS LABORATORIES LTD vs MANKIND PHARMA LTD